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Abstract
Introduction Drug-induced prolongation of the QT
interval on the electrocardiogram (long QT syndrome,
LQTS) can lead to a potentially fatal ventricular arrhythmia
known as torsades de pointes (TdP). Over 40 drugs with
both cardiac and non-cardiac indications are associated
with increased risk of TdP, but drug–drug interactions
contributing to LQTS (QT-DDIs) remain poorly
characterized. Traditional methods for mining observa-
tional healthcare data are poorly equipped to detect QT-
DDI signals due to low reporting numbers and lack of
direct evidence for LQTS.
Objective We hypothesized that LQTS could be identi-
fied latently using an adverse event (AE) fingerprint of
more commonly reported AEs. We aimed to generate an
integrated data science pipeline that addresses current
limitations by identifying latent signals for QT-DDIs in the
US FDA’s Adverse Event Reporting System (FAERS) and
retrospectively validating these predictions using electro-
cardiogram data in electronic health records (EHRs).
Methods We trained a model to identify an AE finger-
print for risk of TdP for single drugs and applied this model
to drug pair data to predict novel DDIs. In the EHR at
Columbia University Medical Center, we compared the
QTc intervals of patients prescribed the flagged drug pairs
with patients prescribed either drug individually.
Results We created an AE fingerprint consisting of 13
latently detected side effects. This model significantly
outperformed a direct evidence control model in the
detection of established interactions (p = 1.62E-3) and
significantly enriched for validated QT-DDIs in the EHR
(p = 0.01). Of 889 pairs flagged in FAERS, eight novel
QT-DDIs were significantly associated with prolonged
QTc intervals in the EHR and were not due to co-pre-
scribed medications.
Conclusions Latent signal detection in FAERS validated
using the EHR presents an automated and data-driven
approach for systematically identifying novel QT-DDIs.
The high-confidence hypotheses flagged using this method
warrant further investigation.
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Key Points
Drug–drug interactions that prolong the QT interval
(QT-DDIs) can can lead to potentially fatal
arrhythmias but remain poorly characterized.
We developed an integrative data science pipeline
that combines mining for latent QT-DDI signals in
the US FDA Adverse Event Reporting System
(FAERS), and retrospective analysis of
electrocardiogram laboratory results in electronic
health records, at Columbia University Medical
Center.
Using latent evidence of long QT syndrome to detect
QT-DDIs in FAERS significantly outperformed use
of solely direct evidence of this adverse event in the
detection of established interactions. The pipeline
significantly enriched for novel QT-DDIs and
identified eight novel interactions that warrant
experimental validation.
1 Introduction
Long QT syndrome (LQTS) is a genetic or acquired change
in the electrical activity of the heart that can increase the
risk of torsades de pointes (TdP), a dangerous ventricular
tachycardia that can lead to sudden cardiac death [1].
Diagnosed using an electrocardiogram (ECG), LQTS is
characterized by a prolonged QT interval and represents an
abnormally increased cardiac action potential duration.
While the link between QT prolongation and TdP is
complex and involves the interplay of multiple factors, a
QT interval[500 ms (vs. a normal range of 350–440 ms)
is nonetheless considered a significant risk for arrhythmo-
genesis [2].
Since the first reports of TdP in the 1960s [3], mutations
in 13 genes coding for cardiac ion channels and their
associated proteins have been found to play roles in LQTS
[1, 4–6]. Congenital LQTS can result from mutations that
disrupt the IKs, IKr, or INa ion currents; however, the
acquired form of LQTS (which is often drug-induced) is
almost exclusively due to block of the human ether-a`-go-
go-related gene (hERG) channel (KCNH2), which plays a
role in the IKr delayed rectifier potassium current respon-
sible for ventricular repolarization [3]. Drug-induced
inhibition of IKr was first discovered for the antiarrhythmic
quinidine [7], and since then over 40 drugs with both
cardiac and non-cardiac indications have been found to
possess either a known, possible, conditional, or congenital
link to dangerously prolonging the QT interval [8]. Ter-
fenadine (an allergy medication) and cisapride (used to
treat acid reflux) were withdrawn from the market in 1997
and 2000, respectively, for prolonging the QT interval [9],
and risk of TdP is now the second leading cause for
approved drug withdrawal [2].
Drug–drug interactions (DDIs) such as those between
methadone (an analgesic) and quetiapine (an antipsychotic)
have also been reported to increase the risk for TdP [10].
Despite the increasingly comprehensive resources available
to clinicians for linking single drugs to TdP, little remains
known about DDIs (QT-DDIs). We define a QT-DDI as a
measurable change in effect (QT interval duration) for a
drug pair compared with the effect observed for either drug
alone. This includes both pharmacokinetic interactions
(such as the increased plasma concentrations of methadone
in patients also taking quetiapine [10]), as well as phar-
macodynamic interactions. While the FDA has required
clinical studies to assess the effects of drug interactions, it
is intractable to prospectively evaluate every possible drug
combination. With DDIs thought to play a role in upwards
of 17 % of adverse events (AEs), and an increasingly aging
population taking multiple drugs concurrently [11, 12],
there is a pressing need for methods to identify potential
interactions.
Molecular mechanism-based approaches such as bio-
logical network analysis have been previously used to
prioritize drugs with molecular links to LQTS genes, but
they remain limited to known drug targets and often only
apply to individual drugs [6]. More recent work using
machine learning on network data can overcome the
requirement for known targets [13]; however, this approach
has only been validated for individual drugs.
Observational healthcare datasets such as the US FDA
Adverse Event Reporting System (FAERS) and electronic
health records (EHRs) provide invaluable resources for
adverse event prediction, but their use is tempered by
multiple limitations. Spontaneous reporting systems such
as FAERS are known to suffer from both reporting bias and
sampling variance [14], and methods for mining FAERS
traditionally rely on direct evidence between a drug
exposure and AE (i.e. the number of reports with the drug
and AE co-mentioned). While methods have been devel-
oped to limit high false positives by correcting for unsub-
stantiated drug–AE signals [15], this leads to a tradeoff
between reducing false positive rates and the ability to
actually detect AEs. Direct detection of AEs falters in the
prediction of DDIs, where reporting numbers are often
lower than for single drugs and unanticipated or unex-
pected events with no understood molecular explanation
can go unreported. A number of advances have been made
in the field, including the observation that additive baseline
models tend to outperform multiplicative ones [16] and that
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case reports can be combined with mechanistic information
such as shared cytochrome P450 (CYP) metabolism to
develop more sophisticated triage algorithms [17].
Nonetheless, most DDI signal detection algorithms have
had limited success [18–20]. Additionally, AE detection in
EHRs can be challenging as such data are often complex,
inaccurate, and missing [21]. While use of either
dataset alone can thus be problematic for QT-DDI detec-
tion, integration of these two sources using data science
offers an opportunity for improved performance.
In previous work, we demonstrated that a novel signal
detection algorithm could be used for detecting latent
signals of previously unknown DDIs for eight severe AE
classes [22, 23]. Importantly, each individual drug in the
drug pair had no previously known connection to the AE
class of interest. In this study, we introduce an updated
pipeline called DIPULSE (Drug Interaction Prediction
Using Latent Signals and EHRs) that uses latent signal
detection in FAERS to generate an AE fingerprint for
LQTS. This AE fingerprint—trained on individual drugs
with a known link to prolonging the QT interval—repre-
sents a profile of more commonly reported side effects that
together are highly predictive of underlying QT interval
prolongation. We apply this fingerprint model to an inde-
pendent test data set of drug pairs to predict new QT-DDIs
where neither drug alone has a known association to this
phenotype. We validate these predictions using ECG lab-
oratory results in EHRs.
2 Methods
A graphical overview of DIPULSE can be found in
Fig. 1. The individual steps of the pipeline corresponding
to each panel of the figure are described in detail below.
Briefly, we used AE reporting frequencies for individual
drugs to identify an AE fingerprint for increased risk of
TdP. We then apply this model to a test data set of AE
reporting frequencies for drug pairs. We filtered for high-
confidence predictions and proceeded to validate these
putative QT-DDIs in the EHR by comparing the QTc
(heart rate-corrected QT) intervals of patients prescribed
the flagged drug pair with patients prescribed either drug
alone. Finally, we perform a confounder analysis to
remove any associations that can be explained by co-
prescribed medications, and generated a final candidate
list of novel QT-DDIs.
In developing the pipeline, our rationale was to priori-
tize high precision over high recall to obtain a final list of
high-confidence interactions; therefore, the choices we
made in designing the filtering steps described below
reflect this conservative approach. We implemented the
method using Python 2.7.9 and R 3.1.0.
2.1 Primary Data Sources
We downloaded a snapshot of the FAERS database con-
taining 1,851,171 reports (corresponding to the first quarter
of 2004 to the first quarter of 2009). Each report in FAERS
contains the drugs prescribed to the patient, the drug
indications, and the observed AEs. We included suspected,
interacting, and concomitant drugs on the reports.
As positive controls, we downloaded a list of 180 drugs
with known (n = 47), possible (n = 75), conditional
(n = 31), or congenital (n = 27) risk of TdP from Credi-
bleMeds, an online compendium of drugs associated with
LQTS [8]. We also obtained a list of 2856 critical and
significant DDIs from the Veteran Affairs Hospital [24].
To validate our DDI predictions, we used EHR data
from Columbia University Medical Center (CUMC). In
addition to patient demographics, drugs prescribed, and
diagnosis codes, we also used QTc (heart rate-corrected QT
interval) values obtained from ECG laboratory results. The
study was approved by the CUMC Institutional Review
Board.
2.2 Generating Adverse Event (AE) Reporting
Frequency Tables
We pre-processed the reports from FAERS to generate the
intermediate AE reporting frequency tables in the OFFSIDES
(single drug) and TWOSIDES (drug pair) databases [25].
OFFSIDES and TWOSIDES were created by training propensity
score matching models to match patients exposed to a
single drug or drug pair to unexposed controls on the basis
of co-prescribed medications and drug indications; an
advantage of this approach is that only patients for whom
controls could be matched are used for drug safety pre-
diction [25].
An intermediate step in this process is the assembly of
AE frequency reporting tables for both single drugs and
drug pairs, as seen in Fig. 1, with each row representing a
drug and each column representing one of the AEs in
FAERS. For single drugs, the value at a given row and
column represents the frequency of reporting Fik, defined
as the fraction of reports for drug i containing the AE
k. Similarly, for drug pairs, the reporting frequency Fijk
corresponds to the fraction of reports for drug pair (i,
j) containing the AE k. We used the former matrix to train
the fingerprint model, and the latter for DDI prediction.
2.3 Training AE Fingerprint Model
We used the AE reporting frequencies (Fik) in the fre-
quency table for single drugs as features to train a logistic
regression classifier. The binary classifier models the log
odds ratio of a drug prolonging the QT interval as a linear
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combination of each AE reporting frequency in the model
multiplied by a weight (known as a b coefficient);
depending on the probability threshold set, a drug above
the threshold is classified as increasing the risk of TdP, and
a drug below the threshold is classified as safe. Training the
model requires both positive and negative examples. As
positive examples, we used the subset of the 47 drugs with
a known risk of TdP in CredibleMeds that were also in
FAERS (n = 23). As negative controls, we selected all
drugs in FAERS that did not appear in CredibleMeds (i.e.
have no known, possible, conditional, or congenital risk of
TdP; n = 530).
Because the number of features (11,305 AEs) is much
greater than the number of examples (553 drugs), overfit-
ting of the model to the training data is a concern. To
ensure the model generalized to our test data set (drug
pairs), we reduced the number of features by using L1
(lasso) regularization [26]. Unlike L2 (ridge) regularization
(which penalizes the squares of the feature weights), L1
regularization penalizes their absolute values and is
therefore preferred because it results in sparse models (i.e.
most of the feature weights will be driven to zero). We
generated five models, each of which contained between 5
and 20 features obtained by varying the regularization
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Fig. 1 Overview of DIPULSE pipeline, which combines mining of
FAERS and EHRs to flag novel QT-prolonging DDIs. FAERS: We
generate an AE reporting frequency table (dimensions, N drugs by
M AEs) for single drugs in FAERS. The value at a row and column
represents the fraction of reports for drug i containing AE k (Fik). We
label a drug as a positive example (shown in red) if it has a known
risk of TdP (obtained from http://www.CredibleMeds.org). All drugs
not found in CredibleMeds were labeled as negative examples (shown
in green). We use machine learning to generate an AE fingerprint
model that identified the most predictive subset of features (AE
reporting frequencies, Fik) as latent evidence for predicting whether a
drug does or does not prolong the QT interval (gray boxes). We then
apply this fingerprint model to an independent test data set consisting
of a matrix (with AE reporting frequencies Fijk) for drug pairs. We
send pairs receiving high classifier probabilities (but where neither
individual drug is known to prolong the QT interval) for EHR
validation (in this case pairs (DN-1, DN-2) [purple-blue] and (DN-1,
DN) [purple-orange]). EHR: We validate putative interactions using
electrocardiogram laboratory results in the EHRs by determining
whether patients prescribed a predicted interacting drug pair had
increased QTc intervals compared with patients taking either drug
alone. In this example, patients prescribed the drug pair (DN-1, DN-2)
have a significantly increased QT interval compared with patients on
either drug alone. This is not observed for drug pair (DN-1, DN) so it
is filtered out. Finally, we performed a confounder analysis to confirm
that the significant increase observed in QTc interval is not due to
other co-prescribed medications. DIPULSE Drug Interaction Predic-
tion Using Latent Signals and EHRs, EHRs electronic health records,
FAERS FDA Adverse Event Reporting System, DDIs drug–drug
interactions, AE adverse event, TdP torsades de pointes, QTc heart
rate-corrected QT interval
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strength for the given model. We evaluated these models
using 10-fold cross-validation, and then re-fit the classifier
using only the selected features. The features for each of
these models constitute an AE fingerprint that represents
latent evidence for QT interval prolongation.
As a control, we generated a logistic regression model
built solely using direct evidence of QT interval prolon-
gation (standardized Medical Dictionary for Regulatory
Activities [MedDRA] query for ‘Torsade de Pointes/QT
prolongation’). There were only six AEs corresponding to
QT interval prolongation or TdP (electronic supplementary
Table 1), and therefore feature selection was not necessary.
2.4 Predicting Novel Drug–Drug Interactions
(DDIs) Using the Fingerprint Model
We next applied the QT fingerprint model to an independent
test data set consisting of the AE reporting frequencies (Fijk)
in the frequency table for drug pairs. The model outputs a
probability for a given drug pair to prolong the QT interval.
We assessed model performance using two references. In the
first, we labeled each drug pair containing a drug known to
increase the risk of TdP as a positive example. While these
may not be bonafide DDIs, they demonstrate the ability of the
fingerprint model to ‘re-discover’ drugs known to prolong
the QT interval within the drug pair data. We used this val-
idation to select the optimal fingerprint model. We also
performed an additional validation using a list of critical and
significant DDIs from the Veteran Affairs Hospital. For both
of these evaluations, we compared the performance of the
‘latent’ AE fingerprint model with the ‘direct evidence’
control model using DeLong’s test [27].
To obtain a candidate list of novel DDIs predicted by the
fingerprint model, we first removed all drug pairs con-
taining a drug in the CredibleMeds list. We then filtered for
all novel predictions found at a classifier probability below
a 4 % false positive rate according to the CredibleMeds
evaluation. We chose this false positive rate threshold by
modeling the expected increase in false discovery rate as a
function of false positive rate (see electronic supplemen-
tary Fig. 1 and accompanying legend for a description of
the analysis). Finally, we removed drug pairs that would
receive high classifier scores regardless of the features used
in the model by generating 100 logistic regression models
using randomly chosen features and estimating empirical
p values for each drug pair. We removed any drug pairs
receiving an empirical p value C0.01.
2.5 Validating Novel DDIs Using Electronic Health
Records
While the novel DDIs predicted using our signal detection
algorithm each contain latent evidence for prolonging the
QT interval, ECG values in EHRs allow us to retrospec-
tively evaluate the effect of these drug pairs (our cases) on
QT interval duration compared with either drug alone (our
controls). Because QT interval durations differ between
males and females [28], we evaluated the effects of a given
drug pair on each sex separately.
To obtain cases, we selected patients at New York-
Presbyterian Hospital/Columbia University Medical Center
who were prescribed each drug in a given drug pair within
a 7-day period. Patients were also required to have an ECG
lab—and corresponding QTc (heart rate-corrected QT
interval)—within 36 days of the second drug prescription.
We chose this limit to minimize the potential for new
confounding drug prescriptions or interventions; addition-
ally, because follow-up visits are often scheduled in units
of weeks, we allowed for 5 weeks plus 1 day for laboratory
tests to be performed [22]. For patients with multiple QTc
values within this time period, we used the maximum
value.
To obtain controls, we selected patients taking which-
ever individual drug in the pair yielded the greatest median
QTc within a 36-day period from drug prescription; we call
this drug the ‘control’ drug. We then compared QTc values
between cases and controls and assessed significance using
a Mann–Whitney U test, correcting for multiple hypothesis
testing using Bonferroni’s method.
In order to demonstrate that the predictions being sent
for EHR validation were enriched for drug interactions that
actually prolonged the QT interval, we ran the above EHR
case-control analysis on a set of drug pairs equal in number
to that generated by the latent signal detection but ran-
domly chosen from the frequency table for drug pairs. To
generate a more representative comparison, we required
that each pair be comprised of a randomly chosen drug
paired with a ‘control’ drug (i.e. the drug with the greatest
QTc interval alone from the latent evidence pairs). Addi-
tionally, to ensure equivalent statistical power we matched
the number of patients in the case groups of the randomly
chosen pairs to the case group sizes of the pairs prioritized
by the latent signal detection. We counted the number of
random pairs that had significant increases in QT interval,
and repeated this sampling procedure 1000 times to build
an empirical distribution of how many significant results
would be expected after EHR analysis by chance alone.
Finally, we adjusted for confounders by confirming that
the elevated QTc interval on the drug pair was not due to
other co-prescribed medications. For each of our sets of
cases (patients on a given drug pair) and controls (patients
on an individual drug in the pair), we identified possible
confounder drugs by counting the number of exposures to
each drug prescribed up to 36 days prior. We evaluated
each potential confounder by confirming that it was cor-
related both with the exposure condition and with QTc
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values. For the former, we determined whether the
covariate was more likely to be prescribed with the drug
pair compared with the single drug using a Fisher’s exact
test; for the latter, we compared the QTc values for patients
exposed to the covariate versus those unexposed using a
Mann–Whitney U test. Both of these evaluations were
performed using a Bonferroni correction for multiple
hypothesis testing. We collected all drug covariates that
passed these two requirements and assessed their signifi-
cance (for males and females separately) using an analysis
of covariance (ANCOVA). To obtain the final list of val-
idated novel DDIs, we only kept those results (drug pairs
for a given sex) receiving significant ANCOVA p values
(p\ 0.05) for the DDI.
3 Results
3.1 QT Fingerprint Model Significantly
Outperforms Model Built Using Only Direct
Evidence
Of the five fingerprint models evaluated, we found that the
model containing 13 features achieved the best perfor-
mance for drug pair data (area under the curve
[AUC] = 0.69 using pairs containing a known Credi-
bleMeds drug) (electronic supplementary Fig. 2); see
Table 1 for the list of features that constitute the QT AE
fingerprint. Importantly, the QT fingerprint model signifi-
cantly outperformed the model built using direct evidence,
as evaluated by both the CredibleMeds (p = 1.62E-3) and
Veteran Affairs (p = 5.22E-10) drug pair standards
(Fig. 2). We also compared these models to a previously
published additive baseline model for predicting DDIs [19]
and found that the latent evidence model outperformed this
method (electronic supplementary Fig. 3; CredibleMeds:
p\ 2.2E-16; Veteran Affairs: p = 2.18E-11). After fil-
tering using both empirical p-values and the 4 % false
positive rate cutoff, we obtained 889 putative novel DDIs
to be validated in the EHR.
3.2 EHR Validation and Confounder Analysis
Confirms Novel Drug Interactions Prolonging
the QT Interval
Our EHR evaluation yielded 49 results (drug pairs for
males and/or females) that had significantly increased QTc
intervals on the drug pair compared with either drug alone
(electronic supplementary Fig. 4). This number of results
was significantly greater than for randomly generated input
to the EHR validation (p = 0.01) (electronic supplemen-
tary Fig. 5). After confounder analysis, we obtained ten
results (corresponding to eight distinct drug pairs) which
represented validated novel DDIs that increase the risk of
acquired LQTS (Table 2).
The greatest increase in median QTc (30 ms) was for
octreotide (a somatostatin analog used to lower growth
hormone levels) and lactulose (administered to treat con-
stipation) compared with octreotide alone (p = 2.48E-4) in
males, and males prescribed this pair were 2 times as likely
to have a QTc interval C 500 ms (electronic supplementary
Table 2). For females, co-prescription of mupirocin and
vancomycin was associated with a 20 ms increase in median
QTc compared with vancomycin alone (p = 1.3E-4);
females prescribed the pair were 1.7 times as likely to have a
QTc interval C 500 ms. A complete list of retrospectively
validated interactions and the number of patients in the case
and control groups can be found in Table 2.
4 Discussion
Drug-induced LQTS and its potential for fatal arrhythmia
(TdP) make this disorder of critical importance both to drug
discovery and pharmacovigilance. Indeed, an important step
in the drug development process is confirming that the lead
compound does not significantly block the hERG channel that
contributes to TdP [2]. However, the inability to prospectively
identify this risk is highlighted by the increasing number of
drugs found to increase the risk for TdP [8]. Even more dif-
ficult to detect are DDIs that contribute to LQTS, as experi-
mental evaluation of all possible QT-DDIs is not feasible and
traditional methods for mining observational data are poorly
equipped to handle low reporting numbers and high false
positive rates. Because analyses of spontaneous reporting
systems (such as FAERS) and EHRs alone have many limi-
tations, in this study we developed an integrative pipeline that
incorporates multiple dimensions of observational data to
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allow for identification of true QT-DDI signals. We demon-
strated the applicability of this data science approach by
identifying latent signals of LQTS in FAERS and retrospec-
tively validating these novel QT-DDI predictions using EHRs.
Comparing our AE fingerprint model for QT prolongation
with a direct evidence control demonstrated that latent evi-
dence of drug-induced LQTS in FAERS can outperform direct
evidence in the detection of established interactions.
While most drugs prolong the QT interval by interacting
with the hERG channel, the clinical data used in this
analysis do not permit a mechanistic explanation for the
synergistic effects of the identified DDIs. Electrophysiol-
ogy experiments to directly assay the effect of individual
drugs and drug pairs on hERG channel activity can provide
further evidence for, and molecular mechanisms of, these
effects [2]. Importantly, QTc correction formulas still used
today were developed in 1920 and are known to be inac-
curate when heart rate changes occur outside the baseline
range used to define the formula [2]. As such, drugs that do
not directly affect ventricular repolarization but instead
alter the patient’s heart rate may be incorrectly attributed to
increasing the QTc. It is possible that some of the inter-
actions we identified were confounded by this complexity.
This limitation highlights the need for experimental vali-
dation of our QT-DDI predictions to directly assess hERG
channel block or effects on other ion channels.
A B
Fig. 2 Receiver operating characteristic curves for adverse event
fingerprint model and direct evidence control. a Model validation was
performed by labeling drug pairs containing a drug with known
increased risk of TdP as positive examples. We compared the
performance of a model built using latent evidence (AE fingerprint
model) to a control model using only direct evidence of QT
prolongation. b A second evaluation performed using a list of critical
and significant DDIs from the Veteran Affairs Hospital in Arizona.
For both validations, the AE fingerprint model significantly outper-
formed the model built solely with direct evidence. Area under the
curve (AUC) is indicated in parentheses. DDIs drug–drug interac-
tions, TdP torsades de pointes, AE adverse event
Table 2 List of novel DDIs generated by DIPULSE and validated in the EHR










Octreotide Lactulose Octreotide M 74.8 2.48E-04 485 455 30 333 603
Mupirocin Vancomycin Vancomycin F 54.5 1.30E-04 476 456 20 810 10,165
Metoprolol Fosphenytoin Metoprolol M 40.9 2.19E-07 462 444 18 549 24,717
N-Acetylcysteine Vancomycin Vancomycin M 17.4 3.74E-04 469 453 16 2633 9789
Cefazolin Meperidine Cefazolin F 27.6 1.29E-05 455 441 14 1025 9172
Cefazolin Meperidine Cefazolin M 18.2 8.97E-08 452 440 12 2110 10,013
Ceftriaxone Lansoprazole Ceftriaxone M 39.1 4.21E-09 458 446 12 934 5734
N-Acetylcysteine Morphine N-Acetylcysteine M 12.1 3.19E-02 460 451 9 2525 6046
Meperidine Vancomycin Vancomycin F 34.6 4.77E-03 464 457 7 1105 9894
N-Acetylcysteine Morphine N-Acetylcysteine F 22.3 7.93E-04 459 455 4 1900 4803
The bolded column highlights the DQTc for a given drug pair
DDIs drug–drug interactions, DIPULSE Drug Interaction Prediction Using Latent Signals and EHRs, EHRs electronic health records, M male,
F female, QTc corrected QT interval
An Integrative Data Science Pipeline to Identify Novel Drug Interactions 439
In considering the features selected for the QT finger-
print model (Table 1), many of the features are expected,
including ECG QT prolonged, TdP, arrhythmia, and even
rhabdomyolysis, as this condition can be induced by
hypokalemia which also predisposes patients to LQTS [3,
29]. However, other features are more unexpected,
including completed suicide and agitation. One explanation
for the selection of these features is that a number of the
positive control drugs (including chlorpromazine, citalo-
pram, and haloperidol) from CredibleMeds are indicated
for conditions characterized by agitation and suicidality.
We purposefully did not manually exclude any features on
the basis of wanting to develop a purely data-driven model
that is not limited to current clinical knowledge of (non-
cardiac) side effects that are highly predictive of underly-
ing QT prolongation; however, because of the relatively
small number of positive controls (predominantly with
psychological, antibacterial, and anti-arrhythmic indica-
tions), we acknowledge the possibility that inclusion of
these features may be driven by the indications of the
positive controls rather than their effects on QT
prolongation.
Our EHR control analysis (while limited to comparing
the number of significant findings prior to confounder
adjustment) demonstrated that our method significantly
enriched for QT-prolonging drug pairs compared with
random selection. Approximately 4 % of pairs investigated
‘passed’ the EHR validation prior to confounder analysis.
Of the 889 pairs flagged by latent signal detection in
FAERS, 251 of these pairs (28 %) had no patients pre-
scribed the pair in our EHR and therefore could not be
evaluated. The other pairs that did not pass validation were
either prescribed at low numbers (and could therefore be
false negatives due to insufficient statistical power) or may
be false positives from FAERS. While we believe the 7-day
window between drug prescriptions represents a fairly
stringent cutoff for confirming that patients were taking
both drugs in a pair concurrently, challenges in estimating
the duration of treatment in EHRs also has implications for
accurately selecting all of the desired patients in the case
group. Follow-up analyses could repeat the EHR analysis
at additional institutions to both replicate these results and
investigate drug pairs that could not be validated in our
EHR.
Because our EHR analysis filtered for interactions (pairs
with significantly greater QT interval prolongation com-
pared with either drug alone), a final potential explanation
for pairs identified in FAERS that could not be validated in
the EHR is that the highlighted pair represented a novel
single drug that prolongs the QT interval. While we limited
the scope of this study to identifying QT-DDIs, resources
such as CredibleMeds continue to use signals in FAERS as
part of their evidence portfolio for the inclusion and
removal of new individual drugs to/from the database [30].
An important challenge to overcome in the evaluation of
potential QT-prolonging single drugs in the EHR would be
the identification of proper controls; propensity score
matching offers one opportunity for addressing this [25].
We note that the AE reporting frequencies for drug pairs
(Fijk) cannot intrinsically distinguish between interactions
and single-drug effects from either drug i or drug j alone.
To distinguish between these two explanations for a drug
pair receiving a high classifier score, it is therefore nec-
essary to remove all single-drug effects (attributable to not
only a known but also possible, conditional, or congenital
link to TdP). CredibleMeds uses a number of signals (in-
cluding FAERS, laboratory and clinical research reports,
and clinical trial data) to populate their database [30].
Thus, while it is possible that CredibleMeds does not
contain complete coverage of all QT-prolonging drugs, we
believe it represents the most reliable resource for justify-
ing removal of drug pairs that receive high scores due to
the effects of single drugs. Application of our method to
other AEs would therefore necessitate a similarly reliable
resource of single-drug effects to minimize the possibility
of falsely labeled interactions. While our confounder
analysis investigated the effects of co-prescribed medica-
tions in addition to the drug pair of interest, follow-up work
could also incorporate the dose of each drug in the pair as a
potential confounder.
While cases of drug-induced LQTS have predominantly
been found to be due to blocking of IKr, we do not discount
the possibility for other potential mechanisms of these QT-
DDIs. Biological network analysis [6, 13] may be useful
for identifying other proteins, in addition to or instead of
hERG, that are affected by these drugs.
5 Conclusions
In this study we have developed and validated DIPULSE,
an automated integrated pipeline for flagging novel DDIs
that can prolong the QT interval using data from both
spontaneous reporting systems (FAERS) and EHRs. By
identifying latent signals of QT interval prolongation, this
method is able to overcome some of the limitations in
mining for DDIs. The method significantly outperforms
DDI detection solely using direct evidence for QT pro-
longation in the detection of established interactions. This
study highlights the utility of integrative data science
approaches in mining for new and potentially fatal DDIs.
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